New shot aims to tame severe childhood eczema
NCT ID NCT06324812
Summary
This study is testing a new injectable medication called '611' for Chinese children and adolescents with moderate to severe atopic dermatitis (eczema). The main goals are to check the drug's safety, how it moves through the body, and whether it can reduce the severity of skin symptoms and itching. The trial involves 124 participants aged 6 to 18 whose eczema hasn't been well controlled with standard creams.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS ATOPIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Children's Hospital
Beijing, Beijing Municipality, 100003, China
Conditions
Explore the condition pages connected to this study.